Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMX
3326
DELISTED
EMX Royalty
EMX
| $174K | ﹤0.01% |
142,500
-6,700
| -4% | -$7.96K |
|
3327
Danaos Corp
DAC
$2.56B
| $173K | ﹤0.01% |
21,365
+7,872
| +58% | +$89.3K |
|
|
OBCI
3328
DELISTED
Ocean Bio-Chem Inc
OBCI
| $173K | ﹤0.01% |
52,600
-2,400
| -4% | -$7.74K |
|
3329
Nortech Systems
NSYS
$35.6M
| $171K | ﹤0.01% |
42,498
-3,102
| -7% | -$12.7K |
|
|
QNRX
3330
Quoin Pharmaceuticals
QNRX
$12.2M
| $171K | ﹤0.01% |
3
+2
| +200% | +$158K |
|
|
APEX
3331
DELISTED
Apex Global Brands Inc. Common Stock
APEX
| $170K | ﹤0.01% |
13,846
+6
| +0% | +$133 |
|
3332
Mind CTI
MNDO
$20.6M
| $169K | ﹤0.01% |
75,754
-26,846
| -26% | -$58.3K |
|
|
THMO
3333
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
| $167K | ﹤0.01% |
+1,322
| New | +$167K |
|
3334
Ocean Power Technologies
OPTT
$55.4M
| $166K | ﹤0.01% |
+86,722
| New | +$220K |
|
3335
Soligenix
SNGX
$8.29M
| $163K | ﹤0.01% |
958
+147
| +18% | +$26.5K |
|
3336
ProQR Therapeutics
PRQR
$261M
| $162K | ﹤0.01% |
17,800
+2,500
| +16% | +$29.5K |
|
3337
SIFCO Industries
SIF
$121M
| $161K | ﹤0.01% |
55,800
+3,300
| +6% | +$9.61K |
|
|
XOMA
3338
DELISTED
Xoma
XOMA
| $159K | ﹤0.01% |
+10,700
| New | +$161K |
|
|
INWK
3339
DELISTED
InnerWorkings, Inc.
INWK
| $159K | ﹤0.01% |
41,700
+30,900
| +286% | +$112K |
|
3340
Immunic
IMUX
$226M
| $157K | ﹤0.01% |
1,373
+1,341
| +4,191% | +$176K |
|
3341
Atlanticus Holdings
ATLC
$1.47B
| $154K | ﹤0.01% |
38,148
+11,848
| +45% | +$41.9K |
|
3342
Edesa Biotech
EDSA
$52.3M
| $151K | ﹤0.01% |
3,062
+1,659
| +118% | +$73K |
|
|
NH
3343
DELISTED
NantHealth, Inc
NH
| $151K | ﹤0.01% |
19,187
+8,834
| +85% | +$89.9K |
|
|
XNET
3344
Xunlei
XNET
$328M
| $149K | ﹤0.01% |
56,800
-59,000
| -51% | -$182K |
|
|
NPTN
3345
DELISTED
NEOPHOTONICS CORP
NPTN
| $149K | ﹤0.01% |
35,658
-129,631
| -78% | -$683K |
|
|
SILV
3346
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
| $148K | ﹤0.01% |
+36,500
| New | +$126K |
|
3347
Citizens Community Bancorp
CZWI
$204M
| $147K | ﹤0.01% |
13,600
-3,100
| -19% | -$35.4K |
|
3348
Barnwell Industries
BRN
$13.9M
| $146K | ﹤0.01% |
129,544
+8,400
| +7% | +$10.9K |
|
|
UFAB
3349
DELISTED
Unique Fabricating, Inc.
UFAB
| $146K | ﹤0.01% |
53,899
+7,503
| +16% | +$25.3K |
|
|
GSV
3350
DELISTED
Gold Standard Ventures Corp.
GSV
| $146K | ﹤0.01% |
138,000
+105,800
| +329% | +$111K |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.